-
World’s largest non-profit organisation dedicated to
commercial use of life science laboratory research tools, reagents, and
materials
- Wholly owned subsidiary of Cancer Research UK
- Partnerships with more than 150 Technology Transfer
Offices, over 2000 researchers and more than 200 life science
companiesworldwide
Partnership with Charles University
- Sale of compounds and other research tools developed at
CUNI through Ximbio’s portfolio (Ximbio.com)
- Ximbio pays CUNI 60 % of revenue generated by offered
compounds
- Researchers are
entitled to up to 55 % of the received sum based on Rector’s Directive
No. 46/2018
- Requires minimum effort on researcher’s side
- Preparation of
compounds in required commercial amounts takes place in Ximbio’s labs
based on provided preparation protocols
- Opportunity to repurpose compounds and tools developed
in research projects and with no further use
- Interest in compounds
and tools both with and without IP protection
Ximbio’s Portfolio
- Monoclonal Antibodies
- Polyclonal Antibodies
- Cell Lines
- Mouse Models
- Small Molecules
- Vectors
- Peptides and Proteins
- Zebrafish
- Recombinant Antibodies
- Lab Consumables
- Bacteria
What Is Required to Provide?
- Structure or any other form of characterisation of
offered research tools
- Preparation protocols
- Optional:
- Small samples for
analyses
- Can be crude (Ximbio
will purify them themselves)
- Data from analyses,
biological testing, etc.
- Information on original
intended use and other potential applications
- Information on expected
biological activity
- Other available relevant documentation
Contact
Dr. Antonín Králík
Analyst and Patent Specialist
Phone: +420 771 134 090
E-Mail: kralik@cuip.cz
